Prostate Cancer: A State of The Heart - European Medical Journal

Prostate Cancer: A State of The Heart

Download PDF
Laurence Klotz1
Alberto Briganti,2 Jan Nilsson,3 Alexandre de la Taille4

LK – Speaker or advisor: Amgen, Astellas, Dendreon, Ferring, GSK, Janssen, Profound Medical, and Sanofi Aventis; AB – Nothing to disclose; AdlT – Consultant or advisor: Astellas, Ferring, Ipsen, Takeda, and PFM; JN – Consultant or advisor: Boehringer Ingelheim, Probi AB.


Writing assistance provided by Dr Tabasum Mughal.


Ferring Pharmaceuticals sponsored this symposium. The views and opinions expressed are those of the authors.

EMJ Urol. ;1[1]:48-53. DOI/10.33590/emjurol/10313656.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Meeting Summary

This symposium was focused on reviewing androgen deprivation therapy (ADT) in prostate cancer, highlighting the implications of this therapy in clinical practice and including a focus on the cardiovascular (CV) risk associated with ADT therapy.

Please view the full content in the pdf above.

Please rate the quality of this content

As you found this content interesting...

Follow us on social media!

We are sorry that this content was not interesting for you!

Let us improve this content!

Tell us how we can improve this content?